Parlodel

Basic Parlodel Information

• INN (International Nonproprietary Name): Bromocriptine
• Brand Names Available In United Kingdom: Parlodel (originator) — tablets commonly 2.5 mg blister packs; Parlodel Sandoz (European generic) — similar 2.5 mg blisters; Bromocriptin-ratiopharm — 2.5 mg tablets; Cycloset (US formulation for diabetes) — noted in regulatory lists but not standard UK use.
• ATC Code: G02CB01 (Bromocriptine). G: Genito-Urinary System And Sex Hormones; G02: Other Gynaecologicals; G02C: Prolactin Inhibitors; G02CB: Prolactin Inhibitors (Ergot Derivatives).
• Forms & Dosages: Tablets 2.5 mg are the standard form sold; 5 mg tablets exist in some countries but are rarer and not universal.
• Manufacturers In United Kingdom: Local supply typically sourced from Novartis/Novartis Sandoz (originator and major European markets) and generics supplied by manufacturers such as Ratiopharm, Teva and Zentiva.
• Registration Status In United Kingdom: Globally approved in most countries for hyperprolactinaemia, Parkinson’s disease and acromegaly; specific national listings vary and prescription status remains Rx only in nearly all markets.
• OTC / Rx Classification: Prescription Only (Rx only).

Latest Research Highlights

Which recent UK and EU studies matter for patients asking about Parlodel and bromocriptine?

Large observational cohorts and registry analyses from 2022–2025 have focused on real‑world tolerability, comparative effectiveness versus newer dopamine agonists and cardiometabolic effects in patients with metabolic syndrome.

These analyses consistently show that bromocriptine often normalises prolactin levels in people with hyperprolactinaemia but that early discontinuation is more common because of nausea and orthostatic symptoms compared with cabergoline.

Pilot cardiometabolic studies in Europe echo earlier non‑UK Cycloset findings, suggesting modest glycaemic benefit at low doses in some patients with metabolic syndrome, though this remains exploratory in UK practice.

Safety surveillance from national regulators and pharmacovigilance reports highlights orthostatic hypotension, psychiatric adverse events in vulnerable groups and rare reports of digital vasospasm.

MHRA and EMA advisories issued in this period continue to stress careful dose titration and extra vigilance in elderly patients during dose escalation.

The net effect in many UK clinics is a prescribing shift towards cabergoline for first‑line treatment of hyperprolactinaemia because of better tolerability and simpler dosing.

Clinical Effectiveness In The UK

What can NHS patients expect when prescribed Parlodel or generic bromocriptine?

When titrated carefully in clinic, bromocriptine reduces prolactin and often restores menses and fertility for women with hyperprolactinaemia.

In Parkinson’s disease it can provide adjunctive symptomatic benefit at lower doses for selected patients, though many neurologists favour non‑ergot alternatives or levodopa regimens for most cases.

NHS audits and specialist clinic experience show biochemical control is achievable but that early discontinuation due to nausea or orthostatic hypotension is more frequent compared with cabergoline.

Practical, measurable endpoints used in UK practice include prolactin normalisation, menstrual resumption, pregnancy rates following treatment, and motor score change for Parkinson’s adjunctive therapy.

• Prolactin normalisation — important biochemical endpoint.
• Menstrual resumption / return of ovulation — common clinical goal.
• Fertility outcomes — pregnancy rates tracked in specialist clinics.
• Motor score change — used where bromocriptine is adjunct in Parkinson’s disease.

Parlodel tablets are most commonly 2.5 mg and the typical starting dose for hyperprolactinaemia is 1.25–2.5 mg once or twice daily, with specialist review for higher doses.

All prescribing is via Rx only routes in the NHS, with electronic prescriptions and pharmacist counselling playing an integral role.

Indications And Expanded Uses

Which conditions is bromocriptine licensed for, and where is it used off‑label?

MHRA and EMA aligned approvals list bromocriptine for hyperprolactinaemia, as adjunctive therapy for acromegaly and as an adjunct in Parkinson’s disease.

In UK practice, private endocrinologists and some NHS specialist centres may use bromocriptine for selected metabolic indications in research contexts, such as metabolic syndrome or NAFLD/MAFLD pilot studies, usually with specialist oversight.

Interest in metabolic uses is informed by the US Cycloset formulation for type 2 diabetes, but UK clinicians remain cautious about routine metabolic prescribing outside trials.

• Hyperprolactinaemia — start 1.25–2.5 mg qd/bid; monitor prolactin and clinical response.
• Acromegaly (adjunct) — start 1.25–2.5 mg qd/bid; monitor IGF‑1 and symptoms; specialist dosing may be higher.
• Parkinson’s disease (adjunct) — begin 1.25 mg qd/bid and titrate under neurology review.

All non‑standard or off‑label uses should involve specialist review and, where possible, enrolment in clinical trials or formal audit.

Remember that bromocriptine remains prescription only and specialist input is recommended for higher doses or less common indications.

Composition And Brand Landscape In The UK And EU

Which brands and manufacturers supply bromocriptine across the UK and EU?

INN is bromocriptine and the active substance is commonly presented as bromocriptine mesilate in product literature.

Tablets of 2.5 mg strength are the standard retail and wholesale form; 5 mg tablets exist in some markets but are less common.

Community trusts and independent pharmacies commonly favour generics from Teva, Ratiopharm or Zentiva for cost control.

Storage guidance across brands is consistent: store at room temperature, protect from excess moisture and light, and keep in the original packaging until use.

Contraindications And Special Precautions

Who should not take Parlodel, and what checks should staff perform before supply?

Absolute contraindications include uncontrolled hypertension, a history of or current severe psychotic disorder and known hypersensitivity to bromocriptine or other ergot alkaloids.

Postpartum use is contraindicated where pre‑eclampsia, eclampsia or significant cardiovascular risk is present.

Relative cautions include cardiovascular disease, hepatic or renal impairment, peptic ulcer history and psychiatric illness; elderly people require slower titration due to higher risk of confusion and hallucinations.

Patients should be advised to avoid driving until individual tolerance is established because dizziness and orthostatic hypotension are common during dose escalation.

Alcohol should be avoided while titrating because it can worsen hypotension and central nervous system effects.

• Initial Screening Checklist: check blood pressure (lying and standing), ECG history, psychiatric history, pregnancy/breastfeeding status and current concomitant medicines.
• Pregnancy/Postpartum: discuss risks with the specialist; routine suppression of lactation is uncommon and has important contraindications.

Dosage Guidelines And Titration

How is bromocriptine started and adjusted in NHS practice?

All regimens follow the principle of starting low and titrating slowly under specialist or prescriber guidance.

For elderly patients and those with hepatic or renal impairment, start at the lower end of the range and titrate more slowly with increased monitoring.

If a dose is missed, take it as soon as remembered unless it is near the next scheduled dose, in which case skip the missed dose and do not double up.

Overdose can cause vomiting, hypotension, confusion, hallucinations and arrhythmia and requires urgent medical assessment.

Interactions Overview

Which drugs, foods and substances interact with bromocriptine and how should pharmacists advise patients?

Bromocriptine’s dopaminergic action leads to important pharmacodynamic interactions with dopamine antagonists and additive hypotension with antihypertensives.

Co‑administration with strong CYP3A4 inhibitors or inducers should be considered cautiously because they may alter bromocriptine exposure, although specific dose adjustments are not universally defined in product literature.

Antipsychotics and antiemetics that block dopamine may reduce bromocriptine efficacy and may precipitate withdrawal‑like issues if such combinations are altered.

Alcohol can worsen hypotension and drowsiness during titration, and excessive caffeine may aggravate tremor or insomnia in Parkinson’s patients.

• Top Interactions To Flag: antipsychotics (dopamine antagonists), antihypertensives (additive hypotension), strong CYP3A4 inhibitors/inducers, dopamine‑blocking antiemetics, alcohol, certain antidepressants (monitor), ergot derivatives (avoid duplication), and medications that increase orthostatic risk.

MHRA Yellow Card reports commonly feature orthostatic syncope, nausea and rare psychiatric events; pharmacists should encourage reporting of suspected adverse reactions via Yellow Card.

Distinguish interaction mechanisms for patients: pharmacodynamic interactions change the drug effect; pharmacokinetic interactions alter the drug concentration in the body.

Cultural Perceptions And Patient Habits In The UK

What do UK patients ask about when prescribed Parlodel or bromocriptine?

Patients in the UK look for clear, NHS‑trusted information and value pharmacist counselling from community chains such as Boots or LloydsPharmacy and independent chemists.

Common forum themes on sites like Patient.info and Mumsnet include concern about nausea and dizziness, a preference for once‑weekly alternatives such as cabergoline and questions about fertility outcomes.

Many patients expect an initial face‑to‑face consultation and tailored advice about side‑effect management, even when prescriptions are issued electronically through e‑consultations or EPS services.

• Typical Patient Concerns: side effects during titration, impact on driving and fertility, comparative queries about cabergoline, and whether the medicine will affect long‑term plans such as pregnancy.

Electronic prescription services and online pharmacies make remote supply easier, but the expectation for pharmacist counselling remains high in the UK.

Availability And Pricing Patterns

Where can patients in the UK obtain Parlodel or generic bromocriptine and what should they expect to pay?

Parlodel and generics are generally available through community pharmacies such as Boots, LloydsPharmacy and independent chemists, and via NHS prescribing routes including electronic prescriptions.

Generics are commonly stocked by NHS trusts and community pharmacies for cost savings, while the originator is also found in retail chains and online suppliers.

Prescription charges differ across the UK; Scotland, Wales and Northern Ireland provide prescriptions free to most patients, while England operates a standard prescription charge for patients who are not exempt.

Pharmacies typically stock 2.5 mg blister packs; 5 mg formulations are less commonly held in routine community stock.

In our online pharmacy, parlodel is available without a prescription, with discreet delivery to United Kingdom in 9-21 days.

For private purchase, generics are usually cheaper than the originator; NHS formularies tend to favour generics for routine supply.

Comparable Medicines And Prescribing Preferences

Which drugs are used instead of bromocriptine, and why?

Cabergoline and quinagolide are the principal comparators for hyperprolactinaemia in UK endocrinology practice.

Cabergoline is often preferred because its longer half‑life and better tolerability reduce dosing frequency and clinic visits, improving adherence.

Quinagolide is an alternative where cabergoline is unsuitable or unavailable, while pergolide has been withdrawn or restricted in many countries and is rarely used.

• Pros/Cons Checklist: Cabergoline — pros: better tolerability, less frequent dosing; cons: cost and availability on some formularies.
• Quinagolide — pros: oral daily dosing, alternative option; cons: not as widely used and availability varies.
• Bromocriptine — pros: effective, familiar to many clinicians; cons: more GI and orthostatic effects, frequent dosing.

In Parkinson’s care, non‑ergot agonists and levodopa remain central, with bromocriptine reserved for selected adjunctive roles under neurology supervision.

FAQ

Will bromocriptine affect fertility?

For hyperprolactinaemia it commonly restores ovulation and menses and can improve fertility outcomes; coordination with your GP and endocrinologist for prolactin monitoring is essential.

Can I drive while taking Parlodel?

Avoid driving during initial titration or while experiencing dizziness or orthostatic symptoms, and inform the DVLA if any persistent impairment affects driving safety.

Is it safe in pregnancy or breastfeeding?

Bromocriptine is usually withheld when pregnancy is desired or confirmed for many prolactinomas unless a specialist advises otherwise; postpartum use for lactation suppression has important contraindications and must be discussed with the prescriber.

How should I manage nausea associated with bromocriptine?

Take the tablet with food, start at a very low dose and titrate slowly and ask your pharmacist about antiemetic strategies if nausea persists.

Urgent Red Flags: seek immediate care for severe hypotension, fainting, sudden confusion or psychosis and persistent vomiting that prevents oral intake.

Guidelines For Proper Use And UK Pharmacist Counselling

What should pharmacists cover when supplying Parlodel or generics in the UK?

Counselling should include the indication, dosing schedule and the importance of starting low and titrating slowly under clinical supervision.

Pharmacists must explain common side effects such as nausea, dizziness and orthostatic hypotension, and provide practical management tips like taking tablets with food.

Discuss what to do if a dose is missed and emphasise not doubling doses, and outline interactions with antihypertensives, antipsychotics and alcohol.

Advise when to seek urgent medical care for syncope, severe hallucinations or persistent vomiting and encourage Yellow Card reporting of suspected adverse reactions.

• Counselling Checklist: indication, start dose, expected side effects, driving advice, alcohol caution, missed‑dose instruction and when to contact the prescriber.

For repeat prescriptions, document counselling in the patient medication record and liaise with the prescriber if side‑effect burden is affecting adherence or a switch to cabergoline may be appropriate.

Provide written medicine information and signpost patients to NHS.uk and specialist endocrinology or neurology services for complex queries.

Delivery Across United Kingdom